Elan Corporation, plc (Elan) is a neuroscience-based biotechnology company. Its operations are organized into two business units: Biopharmaceuticals and Elan Drug Technologies (EDT). Biopharmaceuticals engages in research, development and commercial activities primarily areas, such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis (MS), Crohn’s disease (CD) and severe chronic pain. EDT is a specialty pharmaceutical business unit of Elan. Elan’s marketed products in the the United States include PRIALT (ziconotide intrathecal infusion), AZACTAM (aztreonam for injection, USP) and MAXIPIME (cefepime hydrochloride) for Injection. On June 5, 2006, Elan and Biogen Idec announced the approval of a supplemental Biologics License Application (sBLA) by the United States Food and Drug Administration for the reintroduction of TYSABRI (natalizumab) as a monotherapy treatment for relapsing forms of MS to slow the progression of disability and reduce the frequency of clinical relapses.
